General Mills echoes FedEx with a warning about weaker demand

General Mills echoes FedEx with a warning about weaker demand


Limited Edition holiday breakfast cereal, Christmas Crunch in holiday shapes, Target store, Queens, New York. (Photo by: Lindsey Nicholson/UCG/Universal Images Group via Getty Images)

Lindsey Nicholson | Getty Images

Two big companies weighed in on persistent demand woes this week.

General Mills, which reported earnings Wednesday morning, said tepid demand and pricing pressures are compounding problems for the Dunkaroos and Bisquick maker. That echoed what FedEx said in its report after the bell Tuesday.

FedEx shares fell 10% on Wednesday, on pace for its worst day in 15 months, while General Mills’ stock slipped about 2%.

And, just like FedEx, General Mills trimmed its full-year sales outlook. With two quarters remaining in the Cheerios producer’s fiscal year, the company now sees revenue down 1% to flat, compared with previous guidance of a 3% to 4% increase.

General Mills is also cutting the high end of its earnings guidance due to the lower demand forecast. It expects “a slower volume recovery in fiscal 2024, reflecting a more cautious consumer economic outlook.”

While General Mills reported its eighth consecutive quarterly earnings beat, revenue came up well short of estimates: $5.14 billion vs. $5.35 billion expected, according to LSEG, formerly known as Refinitiv. It was General Mills’ biggest revenue miss in eight years.

CEO Jeff Harmening said the company saw “a slower-than-expected volume recovery in the second quarter amid a continued challenging consumer landscape.”

Organic sales growth was an eyesore, unexpectedly contracting 2% versus Street estimates of 3.1% positive growth. Every business segment saw disappointing sales, from consumer food to pet food, from domestic to international.

Volumes fell 4% overall – led by a 5% drop in North America retail volumes. Pricing increases continued to decelerate, contributing just 3 percentage points to sales in the latest quarter.

The company has also been boosting promotions.

“We’re seeing consumers continue to display stronger-than-anticipated value-seeking behaviors across our key markets, and this dynamic is delaying volume recovery in our categories,” Harmening said in a call with analysts.



Source

FDA chief warns U.S. is losing ground to China in early drug development, calls for faster trial approvals
Business

FDA chief warns U.S. is losing ground to China in early drug development, calls for faster trial approvals

Food and Drug Administration Commissioner Marty Makary warned that the U.S. is falling behind China in early-stage drug development and called for reforms that could streamline the process for starting trials on new treatments.  In an interview with CNBC on Wednesday, Makary specifically pointed to three bottlenecks that he said cause the U.S. to fall […]

Read More
Seattle Seahawks begin sale process after Super Bowl win
Business

Seattle Seahawks begin sale process after Super Bowl win

Dareke Young #83 of the Seattle Seahawks celebrates with teammates during the third quarter of the NFC Championship game against the Los Angeles Rams at Lumen Field on Jan. 25, 2026 in Seattle, Washington. Jane Gershovich | Getty Images The Seattle Seahawks are officially up for sale. The NFL team, which defeated the New England […]

Read More
FDA chief Marty Makary says ‘everything should be over the counter’ unless drug is unsafe or addictive
Business

FDA chief Marty Makary says ‘everything should be over the counter’ unless drug is unsafe or addictive

Food and Drug Administration Commissioner Marty Makary told CNBC that he believes “everything should be over the counter” unless a drug is unsafe, addictive or requires monitoring – doubling down on a push that some in the pharmaceutical industry have questioned.  In an interview Wednesday in Washington, D.C., Makary said the FDA aims to make […]

Read More